Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.06+7.20%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TRDA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advancement of RNA therapy clinical trials and partnerships | A supporting condition in Entrada Therapeutics, Inc.'s published investment case. The stated target is Sustained clinical trial milestones and new partnerships. | Improving | Failure to advance clinical trials or loss of partnerships | Qualitative: Positive topline data (Oct 2026) vs. target of sustained milestones Positive topline data from Phase 1/2 ELEVATE-45-201 study announced Oct 14, 2026, despite some weak dystrophin data reports. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology business, not a proven earnings compounder, because it is loss-making and its programs are still advancing through clinical trials. The long-term thesis is in a watch state: recent data progress is encouraging, but financial performance remains below its industry cohort.
TRDA is valued at a premium to peers, with the model pointing to clinical optionality, or the possibility that programs create future value, as the main source of that premium. The expectations gap is elevated, but model confidence is low, so how much clinical success the market already assumes is uncertain.
Near term, positive topline data from one DMD cohort and continued dosing support management’s clinical milestones, while the next readouts remain important. Cash declined from late 2025 to mid-2026, and management says resources are sufficient into the third quarter of 2027; the litigation filing adds a separate risk. The evidence on near-term operating performance is mixed, despite two reported earnings beats.
Over the multi-year view, the central swing factor is whether upcoming DMD data support continued development of the programs, including planned readouts by year-end 2026. The thesis also depends on cash runway remaining adequate as the trials advance. Near term, guidance cuts or weaker employment data could add pressure, while stronger results and guidance from healthcare sector bellwethers could support sector momentum.
TRDA’s multi-year view rests on clinical execution and funding runway, not current earnings, and both remain uncertain. Progress is visible, but the premium valuation and elevated business risk make upcoming data especially important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS loss narrows from -$3.79 in 2026 to less negative in 2027 | A primary condition in Entrada Therapeutics, Inc.'s published investment case. The stated target is EPS loss improves to > -$3.26. | Improving | EPS loss worsens beyond -$3.79 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to reverse decline and approach $29.8M in 2027 | A primary condition in Entrada Therapeutics, Inc.'s published investment case. The stated target is >= $29.8 million. | Broken | revenue falls below $15 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.59 → $-3.58 · observed estimates
$0.03B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.59 | $26,082,875 | 6 / 5 |
| 2026-07-25 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-07-26 | $-3.59 | $26,082,875 | 6 / 5 |
| 2026-07-27 | $-3.59 | $26,082,875 | 6 / 5 |
| 2026-07-28 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-07-29 | $-3.59 | $26,082,875 | 6 / 5 |
| 2026-07-30 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-07-31 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-08-01 | $-3.59 | $26,082,875 | 6 / 5 |
| 2026-08-02 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-08-03 | $-3.59 | $26,082,875 | 6 / 5 |
| 2026-08-04 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-08-05 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-08-06 | $-3.26 | $29,809,000 | 6 / 7 |
| 2026-08-08 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-09 | $-3.27 | $40,790,000 | 7 / 5 |
| 2026-08-10 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-12 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-13 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-14 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-15 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-16 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-17 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-18 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-19 | $-3.50 | $25,939,875 | 6 / 5 |
| 2026-08-20 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-21 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-22 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-23 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-24 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-25 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-26 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-27 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-28 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-29 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-30 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-08-31 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-09-01 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-09-02 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-09-03 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-09-04 | $-3.37 | $20,002,375 | 6 / 6 |
| 2026-09-05 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-06 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-07 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-08 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-09 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-10 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-11 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-12 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-13 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-14 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-15 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-16 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-17 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-18 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-19 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-20 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-21 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-22 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-23 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-24 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-25 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-26 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-27 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-28 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-29 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-09-30 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-01 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-02 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-03 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-04 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-05 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-06 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-07 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-08 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-09 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-10 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-11 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-12 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-13 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-14 | $-3.37 | $20,002,375 | 6 / 5 |
| 2026-10-15 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-16 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-17 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-18 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-19 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-20 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-21 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-22 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-23 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-24 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-25 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-26 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-27 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-28 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-29 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-30 | $-3.37 | $20,006,250 | 6 / 5 |
| 2026-10-31 | $-3.58 | $17,507,143 | 6 / 5 |
| 2026-11-01 | $-3.58 | $17,507,143 | 5 / 5 |
| 2026-11-02 | $-3.58 | $17,507,143 | 5 / 5 |
| 2026-11-03 | $-3.58 | $17,507,143 | 5 / 4 |
| 2026-11-04 | $-3.58 | $17,507,143 | 5 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.